Skip to content
★ Sign in to follow
Anhui Hongyu Wuzhou Medical Manufacturer Co.,Ltd. logo

Anhui Hongyu Wuzhou Medical Manufacturer Co.,Ltd. Stock: price and insider trades · China

五洲医疗

CN·Mcap CN¥8.7BHealth Care

Anhui Hongyu Wuzhou Medical Manufacturer Co.,Ltd.: what insiders have been doing

This page follows insider dealings at Anhui Hongyu Wuzhou Medical Manufacturer Co.,Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. The last twelve months, up to 5 November 2026, brought 3 filings signed by 2 insiders.

There is no open-market purchase to report; the filings show 3 sales worth €37k by 2 insiders. 周乐翔 filed the largest sale, €25k, on 7 November 2025.

For context, the typical company on the same exchange (median of 519 companies) published 2 filings over the same period, against 3 filings here. Over the whole record (from 2025), the tally stands at no purchases and 4 sales.

Publication is fast: at least half of the trades appear on SSE / SZSE (CSRC) on the same day. The shorter that gap, the sooner other investors can see what insiders have done. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€142,166
4 ops. · all time

Who traded when

BuySale
周乐翔2 sales
潘岚岚2 sales

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 16,663 of 26,914 companies
44.0
score / 100
Value
38
Quality
51
FCF yld0.6%
Earn yld0.2%
EV/EBITDA·
ROE3.1%
Gross mgn15%
Net mgn4.1%
Debt/EBITDA0.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥127.22
Analyst consensus
·
Income statement
RevenueCN¥458.3M
Gross profitCN¥66.8M15% margin
EBITDACN¥61.8M13% margin
Net incomeCN¥18.9M5.3% margin
Valuation
PER (trailing)363.5x
P/Book11.3x
Beta-0.02
Balance sheet & cash
Market capCN¥8.7B
Total debtCN¥254.6k
Free Cash FlowCN¥53.6M
Debt / Equity0%
Profitability & ownership
ROE3.1%
ROA1.7%
% insiders69.1%
% institutions1.3%
Last declaration on 19 November 2025
Declarations4 total
  • ▼
    董秘,董事,高管Executives
    85,029 CNY27SZSE
    2,100 shares80.8% of flowA股XSHESZSE:173000009805094300
  • ▼
    董秘,董事,高管Executives
    20,205 CNY21SZSE
    500 shares19.2% of flowA股XSHESZSE:173000009801096900
  • ▼
    监事Executives
    202,500 CNY9SZSE
    5,000 shares19.0% of flowA股XSHESZSE:173000009726567680
  • ▼
    监事Executives
    867,000 CNY15SZSE
    20,000 shares81.0% of flowA股XSHESZSE:173000009695159460

4 of 4 declarations

About Anhui Hongyu Wuzhou Medical Manufacturer Co.,Ltd.

五洲医疗 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It focuses on the development and distribution of medical and pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations